Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Govt to Temporarily Exempt Tamiflu, Relenza from Tariffs; Green Cross Begins H1N1 Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The Korean government will temporarily exempt Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) from a tariff and a local value-added tax until the end of next year as part of an effort to help local A/H1N1 flu patients get fast and easy access to treatments at lower costs

You may also be interested in...



Korea's Green Cross in Talks with MNCs Over A/H1N1 Vaccine Adjuvants

SEOUL - Amid rising concerns that the government may have to import substantial doses of an A/H1N1 flu vaccine soon from other countries, including China, South Korean vaccine maker Green Cross said it is currently in talks with multinational companies to buy the adjuvants used in production of the flu vaccine

Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister

SEOUL - Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) could be manufactured under compulsory licensing in South Korea if the country faces an emergency swine flu threat in the coming months, Health, Welfare and Family Affairs Minister Jeon Jae-Hee said

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel